Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Antengene Announces Five Upcoming Presentations at the 2023 American Association for Cancer Research Annual Meeting 2023-03-20 15:20
Antengene Announces IND Approval for the Phase I CLINCH Trial of ATG-022 (Claudin 18.2 ADC) for the Treatment of Advanced or Metastatic Solid Tumors in China 2023-03-14 12:29
Antengene to Present at the 41st Annual J.P. Morgan Healthcare Conference 2023-01-03 14:10
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA® (pembrolizumab) 2022-12-27 08:30
Antengene Announces NDA Submission for XPOVIO® in Macau, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma 2022-12-23 08:30
Antengene Announces HREC Approval in Australia for the Phase I Trial of ATG-022 (Claudin 18.2 ADC) in Patients with Advanced or Metastatic Solid Tumors 2022-12-09 08:30
Antengene Appoints Amily Zhang as its Chief Medical Officer 2022-12-08 08:30
Antengene Highlights Encouraging ATG-008 Efficacy Results From TORCH-2 Study in Combination with PD-1 Antibody in Relapsed/Metastatic Cervical Cancer 2022-11-15 16:51
Antengene Presents Promising Results from Four Preclinical Studies at the 2022 Society for Immunotherapy of Cancer Annual Meeting 2022-11-11 08:30
Preliminary Results from Two Clinical Studies of Selinexor to be Presented at 2022 ASH Annual Meeting 2022-11-07 14:38
Antengene Announces IND Approval for the Phase I STAMINA-001 Study to Evaluate ATG-037 (CD73 Inhibitor) for the Treatment of Locally Advanced or Metastatic Solid Tumors in China 2022-11-02 20:07
Antengene Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors 2022-10-31 20:22
Antengene to Host Research and Development Day on November 15th and 17th, 2022 2022-10-27 11:07
Antengene Announces XPOVIO® Regulatory Approval in Taiwan for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma 2022-10-21 20:37
Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting 2022-10-08 10:43
Antengene Announces ATG-101 Granted Orphan Drug Designation by the U.S. FDA 2022-09-19 09:34
Antengene Unveils Its First Australian Office to Continue Expanding Global Presence 2022-09-14 08:30
Antengene to Present at Upcoming Industry Conferences 2022-09-09 14:43
Antengene Announces XPOVIO® Included for Reimbursement by the PBS in Australia for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma 2022-09-01 08:30
Antengene Announces Interim 2022 Financial Results and Provides Corporate Update 2022-08-31 08:29
1 2 3 4 5 8